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ABSTRACT
Anoikis resistance is a hallmark of cancer, and relates to malignant phenotypes, including chemoresistance, 
cancer stem like phenotypes and dissemination. The aim of this study was to identify key factors contributing to 
anoikis resistance in ovarian cancer using a functional genomics screen. A library of 81 000 shRNAs targeting 15 
000 genes was transduced into OVCA420 cells, followed by incubation in soft agar and colony selection. We found 
shRNAs directed to ABHD2, ELAC2 and CYB5R3 caused reproducible anoikis resistance. These three genes are deleted 
in many serous ovarian cancers according to The Cancer Genome Atlas data. Suppression of ABHD2 in OVCA420 
cells increased phosphorylated p38 and ERK, platinum resistance, and side population cells (p<0.01, respectively). 
Conversely, overexpression of ABHD2 decreased resistance to anoikis (p<0.05) and the amount of phosphorylated 
p38 and ERK in OVCA420 and SKOV3 cells. In clinical serous ovarian cancer specimens, low expression of ABHD2 was 
associated with platinum resistance and poor prognosis (p<0.05, respectively). In conclusion, we found three novel 
genes relevant to anoikis resistance in ovarian cancer using a functional genomics screen. Suppression of ABHD2 
may promote a malignant phenotype and poor prognosis for women with serous ovarian cancer.
INTRODUCTION
Ovarian cancer is the most lethal cancer among 
gynecologic malignancies [1]. New treatment strategies 
are urgently need to help improve prognosis. To this 
end, it is important to elucidate the detailed molecular 
characteristics of ovarian cancer. There are several 
pathological phenotypes of ovarian cancer. High-grade 
serous ovarian cancer (HGSOC) is the most frequent 
subtype with a very poor prognosis [2].
Recently, genomic analyses of HGSOC, including 
The Cancer Genome Atlas (TCGA) project, have begun 
to shed light on many of the genetic and epigenetic 
features of these tumors [3]. From TCGA findings, HGSOC 
is characterized by ubiquitous TP53 mutations and 
extensive copy number alterations. However, it is unclear 
which of the numerous genome-wide genetic changes 
are involved in the HGSOC carcinogenic process.
Cultured non-transformed cells can survive 
exclusively in anchorage-dependent conditions. 
When loss of cell-cell and/or cell-matrix interactions 
occurs, cell death ensues. This is termed anoikis, and 
resistance to anoikis is a common feature of cancer cells 
[4]. In addition to carcinogenesis, anoikis resistance 
also relates to cancer stem cell (CSC) like phenotypes, 
chemoresistance, and propensity to metastasize [5, 6, 7]. 
However, not all cancer cells are resistant to anoikis. We 
previously reported that some HGSOC cell lines do not 
attain anoikis resistance [8]. Several oncogenic signaling 
pathways are involved in resistance to anoikis. In HGSOC, 
anoikis resistance is related to phosphorylation of 
ERK1/2, p38MAPK, JNK and Src [5, 9, 10, 11].
A functional genomics screen is an effective 
method to identify genes that are truly responsible 
for specific functions or phenotypes among various 
genetic alterations that occur in cancer cells. The use of 
an shRNA library is one of the most effective research 
tools to carry out functional genomics screening [12]. 
Recently, novel tumor suppressor genes in colon cancer 
and breast cancer were identified through functional 
genomics screening using an shRNA library [13, 14]. 
There are several reports of functional genomics screens 
using shRNA libraries in ovarian cancer [15, 16, 17]. 
However, to our knowledge this is the first functional 
genomics screen to select shRNAs that enable ovarian 
cancer cells to grow in anchorage-free conditions. We 
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chose to use soft agar colony formation assays since they 
have commonly been used for evaluating resistance to 
anoikis as well as for functional genomics screens [18, 
19].
We analyzed the status of the identified genes in 
clinical samples. Our results suggest a novel approach 
to identify genes functionally responsible for malignant 
phenotypes of HGSOC and the various genetic alterations 
that occur in this disease.
RESULTS
Functional genomic screening
First shRNA library screening
Schematics of the functional genomics screens used 
are shown in Figure 1a.
We previously reported on seven serous ovarian 
cancer cell lines, including OVCA420, OVCA433, 
OVCA429, TYK-nu, SKOV8, CAOV3 and DOV13, that 
do not exhibit anchorage-independent cell proliferation 
[8]. These seven serous ovarian cancer cell lines and 
HOSE-E7 [20] were used in the first screening. We 
transduced the DECIPHER RNAi library Module 
(Cellecta, Mountain View, USA), a pRSI12-based 
backbone lentiviral shRNA library comprising ~80,000 
plasmids targeting ~15,000 genes, into cells according 
to the manufacturer’s instructions. Using the pRSI12 
backbone control vector, we carefully repeated preliminary 
experiments to find optimal conditions for transduction 
of all kinds of shRNA constructs into cells. Using these 
conditions, we transduced an shRNA library into cells at a 
high multiplicity of infection (>0.5). Following 72 hours 
of selection with puromycin, 3.6x106 stably transduced 
cells were suspended in 0.3% soft agar with 1x media for 
soft agar colony assays. On day 21, only OVCA420 cells 
(among the eight cell lines) formed anchorage independent 
colonies >100 μm following shRNA library transduction. 
They were selected under a microscope and individually 
expanded. Forty-three colonies were successfully 
expanded, from which we extracted DNA for subcloning.
Subcloning and reconstruction of shRNA 
plasmids, followed by a second screening
We conducted a second screen using shRNAs 
selected in the first screen by reconstructing lentiviral 
plasmids. The shRNA target sequences were located 
between the ClaI and XbaI restriction sites in the pRSI12 
lentiviral vector. We amplified shRNA target sequences 
by PCR from DNA extracted from the colonies that were 
grown in soft agar. The amplified PCR products were 
subcloned into the original pRSI12 lentiviral vector at the 
ClaI and XbaI sites, thus reconstructing pRSI12 shRNA 
lentiviral plasmids. Because multiple shRNA plasmids 
could be represented in one colony, we subcloned at 
least five clones per PCR amplicon. We identified 69 
different shRNAs by Sanger sequencing, targeting 66 
genes (Supplementary Table S1). In the second screen, 
we transfected the 69 reconstructed lentiviral shRNA 
plasmids into OVCA420 cells individually and performed 
soft agar colony formation assays. We repeated the second 
screen in triplicate, confirming reproducibility. On day 21, 
11 shRNA plasmid-transduced OVCA420 cells formed 
colonies >100 μm in diameter (Supplementary Table S2) 
and thus were regarded as reproducible effects of these 
shRNAs. We then evaluated mRNA expression in the 11 
different shRNA-transduced OVCA420 cells by RT-PCR 
to exclude off-target effects. We found that three different 
shRNA plasmids, whose target genes were ABHD2, 
ELAC2 and CYB5R3, suppressed mRNA expression of 
their targets (p=0.03, p=0.0202, p=0.002, respectively, 
Figure 1b-1d).
Expression and copy number alterations of 
ABHD2, ELAC2 and CYB5R3
We next investigated gene expression and potential 
copy number changes for ABHD2, ELAC2 and CYB5R3 
in clinical samples. For ABHD2, mRNA expression was 
significantly lower in ovarian cancer than that in serous 
borderline tumors (SBT) (p=0.001; GSE9891, p=0.006; 
GSE2109, Figure 2a). In addition, among the ovarian 
cancers, expression was significantly lower in HGSOC 
than that in non-HGSOC (p=0.02; GSE2109, Figure 2b). 
Furthermore, loss of the ABHD2 locus at 15q26.1 was 
frequent in HGSOC samples from the TCGA dataset 
(41.8%, Figure 2c). We found a positive correlation 
between copy number and mRNA expression (r=0.476, 
p<0.0001, Figure 2d). Additionally, we investigated 
ABHD2 protein expression in clinical samples by 
immunohistochemistry. Consistent with the observed 
reduction in mRNA, there was a statistically significant 
reduction in ABHD2 protein expression in HGSOC (n=36) 
as compared to SBT (n=8) and normal fallopian tube 
(n=11) (p=0.005 and p=0.013, respectively, Figure 2e).
Like ABHD2, ELAC2 and CYB5R3 mRNA levels 
were significantly lower in ovarian cancer than in SBT 
(p=0.008 and 0.003, respectively, Figure 3a, Figure 4a). 
ELAC2 expression in cancer was also lower than that 
in normal ovarian epithelium (p=0.005, Figure 3a). 
Comparing histologic subtypes of epithelial ovarian 
cancers, ELAC2 and CYB5R3 mRNA levels were 
significantly lower in HGSOC than in non-HGSOC 
(p<0.0001, p=0.03, respectively, Figure 3b, Figure 4b). In 
the TCGA dataset, genomic deletions at ELAC2 (17p11.2) 
and at CYB5R3 (22q13.2) were frequent in HGSOC 
(84.2% and 83.5%, respectively, Figure 3c, Figure 4c). 
Both showed positive correlations between mRNA 
levels and the copy number reported (ELAC2; r=0.539, 
p<0.0001, CYB5R3; r=0.485, p<0.0001, Figure 3d, 
Figure 4d).
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Next, we analyzed promoter methylation and also 
looked for the presence of DNA mutations for the three 
genes identified from the HGSOC TCGA data. Except for 
two cases that had a missense mutation in ABHD2, there 
were no other mutations in the three genes (data not 
shown). ELAC2 and CYB5R3 were mostly unmethylated 
(Supplementary Figure S1a). ABHD2 showed some 
evidence of methylation (Supplementary Figure S1a), 
but when we analyzed the extent of methylation in 
the promoter region of ABHD2 in two ovarian cancer 
cell lines (HEYA8 and A2780) and eight HGSOC samples 
by bisulfite sequencing, we found that there were 
few methylated CpG dinucleotides in the promoter 
region. (Supplementary Figure S1b, S1c). Therefore, 
we concluded that promoter methylation and DNA 
mutations play a minimal role in the regulation of 
expression for these three genes in HGSOC.
In summary, altered ABHD2, ELAC2 and CYB5R3 
mRNA expression was identified through our functional 
genomics screen and was significantly reduced in 
ovarian cancer, especially in HGSOC, relative to that in 
SBT or normal ovarian epithelium. In addition, these 
genes are located in loci that are frequently deleted 
in HGSOC. A positive correlation between mRNA 
expression levels and copy number was detected for all 
three genes.
Figure 1: Schematic of functional genomics screens. a. Seven human ovarian serous adenocarcinoma cell lines and an immortalized 
human ovarian surface cell line HOSE/E7, all of which do not grow in soft agar, were used. Following transfection of the shRNA library, 
only OVCA420 cells formed colonies in soft agar. 43 colonies were successfully expanded. shRNAs were amplified by PCR and we 
reconstructed 69 different shRNA plasmids. Out of the 69 shRNAs in OVCA420 cells, 11 again generated colonies in soft agar. We 
then measured mRNA expression of these 11 genes using RT-PCR. Of the 11 shRNAs, shRNAs directed against ABHD2, CYB5R3 and 
ELAC2 suppressed target gene mRNA expression. b. Left: shRNA-ABHD2 transfected OVCA420 cell colony in soft agar. Black bar, 100 
μm. Right: normalized ABHD2 / ACTB mRNA expression analyzed by RT-PCR. (n=3, respectively) c. Left: shRNA-ELAC2 transfected 
OVCA420 cell colony in soft agar. Right: normalized ELAC2 / ACTB mRNA expression. d. Left: shRNA-CYB5R3 transfected OVCA420 
cell colony in soft agar. Right: normalized CYB5R3 / ACTB expression.
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Validation of ABHD2 as a negative regulator of 
anoikis resistance
Among the three genes that we identified, mRNA 
expression levels of ABHD2 were related to prognosis 
(described below). We therefore focused on the role of 
ABHD2 in ovarian cancer.
We transduced ABHD2-specific shRNAs, different 
from those used for the functional screening, and non-
silencing control shRNA plasmids into OVCA420 cells, 
and established sh1-OVCA420, sh2-OVCA420 and 
control-OVCA420, respectively (Supplementary Figure 
S2a). We confirmed that both ABHD2 mRNA and protein 
expression were suppressed in sh1-OVCA420 and sh2-
OVCA420 compared to those in control-OVCA420 by 
RT-PCR and Western blotting (Supplementary Figure 
S2a). To assess resistance to anoikis, we employed a more 
quantitative method than the colony formation assay. We 
cultured cells in ultra-low attachment dishes and counted 
viable cells after seven days. We found that both sh1-
OVCA420 and sh2-OVCA420 cells had significantly 
enhanced survival relative to the control-OVCA420 cells 
(Figure 5a). Next we assessed the expression of AnnexinV, 
a marker of apoptosis, following incubation in ultra low 
attachment dishes for 24 hours. Expression of AnnexinV 
in sh1-ABHD2, sh2-ABHD2 OVCA420 cells was 
significantly lower than that of control OVCA420 cells 
(Figure 5b, 5c). Therefore, suppression of ABHD2 caused 
resistance to apoptosis under anchorage-free conditions, 
which has also been referred to as anoikis resistance. 
There was no significant difference in proliferation 
for the sh1-OVCA420, sh2-OVCA420 and control-
Figure 2: ABHD2 mRNA, protein expression and copy number in clinical specimens. mRNA expression was evaluated 
using log2 normalized values. a. Comparison of ABHD2 mRNA expression between ovarian cancer tissues and serous borderline tumors 
(SBT) using gene expression microarray datasets GSE9891 and GSE2109. b. Comparison of ABHD2 mRNA expression between serous 
adenocarcinoma and non-serous adenocarcinoma in microarray dataset GSE2109. c. Copy number alterations for ABHD2 in TCGA 
samples. Del; deletion, Amp; Amplification. d. Correlation between ABHD2 copy number and mRNA expression in TCGA specimens. 
e. Representative ABHD2 immunohistochemistry staining for HGSOC (intensity 0, 1 and 2), normal fallopian tube and SBT are shown. 
Comparison of H-scores among HGSOC, fallopian tube and SBT. The H-score is calculated as 2x the percentage of the most strongly 
stained area plus 1x the percentage of the most weakly stained area, imparting a total score ranging from 0 to 200.
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OVCA420 cells grown in standard tissue culture dishes 
(Supplementary Figure S3a). We established ABHD2-
overexpressing OVCA420 cells by transfecting the cells 
with an expression plasmid containing the open reading 
frame of ABHD2 (Supplementary Figure S2b) (referred 
to hereafter as OVCA420-ABHD2 cells) and assessed 
their resistance to anoikis. OVCA420-ABHD2 cells had 
significantly lower resistance to anoikis relative to that 
of OVCA420 cells transfected with the vector control 
plasmid (OVCA420-control cells) (Figure 5d).
We next transduced SKOV3 cells with a plasmid 
containing the open reading frame of ABHD2 or a vector-
only control plasmid, establishing SKOV3-ABHD2 cells 
and SKOV3-control cells, respectively (Supplementary 
Figure S2c). We confirmed elevated expression of ABHD2 
mRNA and protein in SKOV3-ABHD2 cells compared to 
SKOV3-control cells using RT-PCR and Western blotting 
(Supplementary Figure S2c). We assessed resistance to 
anoikis in the same way as described above, and found 
that SKOV3-ABHD2 cells were less able to survive in an 
ultra-low attachment dish than were the SKOV3-control 
cells (Figure 6a). When we incubated SKOV3-ABHD2 
and control cells on ultra-low attachment dishes for 48 
hours, AnnexinV expression was significantly higher in 
SKOV3-ABHD2 cells relative to SKOV3-control cells 
(Figure 6b, 6c). In standard tissue culture dishes, there was 
no difference in proliferation between the SKOV3-ABHD2 
and SKOV3-control cells (Supplementary Figure S3b). 
Furthermore, we transfected SKOV3-ABHD2 cells with 
control shRNA, ABHD2-specific shRNA-1 or ABHD2-
specific shRNA-2 to establish control-SKOV3-ABHD2, 
sh1-SKOV3-ABHD2 and sh2-SKOV3-ABHD2 cells 
(Supplementary Figure S2d). Anoikis resistance, assessed 
by AnnexinV expression following incubation on ultra-
Figure 3: ELAC2 mRNA expression and copy number in clinical specimens. mRNA expression was evaluated using the log2 
normalized values. a. Comparison of ELAC2 mRNA expression between ovarian cancer tissue and SBT or normal ovarian epithelium 
from the gene expression microarray datasets GSE9891 and GSE6008. b. Comparison of ELAC2 mRNA expression between serous 
adenocarcinoma and non-serous adenocarcinoma in microarray dataset KOV-75. c. Copy number alterations at ELAC2 in TCGA specimens. 
d. Correlation between ELAC2 copy number and mRNA expression in the TCGA dataset.
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low attachment dishes, was significantly increased in 
sh1-SKOV3-ABHD2 and sh2-SKOV3-ABHD2 cells as 
compared to the control-SKOV3-ABHD2 cells (Figure 
6d, 6e, 6f ).
We overexpressed or suppressed ABHD2 
expression in RMG1, an ovarian clear cell carcinoma cell 
line. Then we could not find significant difference among 
control , ABHD2-overexpressed and ABHD2-suppressed 
cells (in terms of anoikis resistance (data not shown.)
As a result, we could find that ABHD2 expression 
regulated anoikis resistance of HGSOC.
Analysis of intracellular signaling relevant to 
anoikis resistance
We examined phosphorylation of ERK1/2, 
p38MAPK, JNK and Src by Western blotting since they 
have been reported as relevant to anoikis resistance in 
ovarian cancer [5, 9, 10, 11]. Phosphorylation of ERK1/2 
and p38MAPK was increased in sh1-OVCA420 and 
sh2-OVCA420 cells compared to control-OVCA420 
(Figure 7a). Consistent with these results, phosphorylation 
was decreased in both SKOV3-ABHD2 and OVCA420-
ABHD2 cells as compared to SKOV3-control and 
OVCA420-control cells, respectively (Figure 7a). We did 
not detect any difference in phosphorylation status for 
JNK and Src (data not shown).
We next assessed the effects of specific inhibitors 
of the ERK (GSK1120212) or p38MAPK (SB203580 ) 
pathways [21, 22]. Treatment with both GSK1120212 and 
SB203580 decreased anoikis resistance that was primed by 
suppression of ABHD2 in OVCA420 cells (Figure 7b, 7c). 
Phosphorylation of ERK1/2 and p38MAPK was increased 
in sh1-SKOV3-ABHD2 and sh2-SKOV3-ABHD2 cells as 
compared to control-SKOV3-ABHD2 cells (Figure 7d). 
Following incubation in ultra-low attachment dishes, the 
Figure 4: CYB5R3 mRNA expression and copy number in clinical specimens. mRNA expression was evaluated using the log2 
normalized value. a. Comparison of CYB5R3 mRNA expression between ovarian cancer tissue and SBT in the gene expression microarray 
dataset GSE9891. b. Comparison of CYB5R3 mRNA expression between serous adenocarcinoma and non-serous adenocarcinoma in 
microarray datasets KOV-75 and GSE2109. c. Copy number alterations of CYB5R3 in TCGA specimens. d. Correlation between CYB5R3 
copy number and mRNA expression in the TCGA dataset.
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number of viable sh1-SKOV3-ABHD2 and sh2-SKOV3-
ABHD2 cells was significantly decreased when the cells 
were treated with GSK1120212, a specific inhibitor of the 
ERK1/2 pathway, or SB203580, a specific inhibitor of the 
p38MAPK pathway (Figure 7e). These results indicate 
suppression of ABHD2 enhances anoikis resistance 
in ovarian cancer via activation of both ERK1/2 and 
p38MAPK pathways.
Association of ABHD2 expression and 
clinicopathological factors in HGSOC
We investigated the relationship between ABHD2 
protein expression and clinicopathological factors in 
HGSOC, including patient age, FIGO stage, ascites 
cytology, lympho-vascular invasion (LVSI), lymph 
node metastasis, platinum resistance and prognosis. We 
regarded patients who recurred within one year from 
completion of treatment as platinum-resistant cases as 
has been previously reported [23]. As a result, we found 
there were significantly more platinum-resistant patients 
in the low-ABHD2 group than in the high-ABHD2 group 
(p=0.013, Table 1 ). The prognosis of the low-ABHD2 
group patients was significantly worse as compared to that 
of the high group patients (p=0.005, Figure 8a), although 
it was not an independent prognostic factor. In accordance 
with this result, in two expression microarray datasets of 
ovarian cancer consisting mostly of HGSOC (GSE9891, 
GSE3149), the prognosis of the low ABHD2 expression 
group was significantly worse as compared to that of 
the high ABHD2 expression group (p=0.013, p=0.04, 
respectively, Figure 8b).
In order to examine if differences between 
histological subtype affect the difference in prognosis, 
we divided the KOV-75 gene expression microarray 
specimens into HGSOC (n=36) and non-HGSOC (n=39). 
There were no significant differences in prognosis based 
on expression levels of ELAC2 or CYB5R3 in HGSOC 
versus non-HGSOC (data not shown). Similarly, there 
was no significant difference in prognoses based on 
expression levels of ABHD2 in the non-HGSOC cases 
(Figure 8c). However, the prognosis of the low-ABHD2 
expression group was significantly worse in HGSOC 
(p=0.001, Figure 8d). Thus, low expression of ABHD2 
is significantly related to platinum-resistance and a poor 
prognosis for HGSOC. We also analyzed expression of 
ELAC2 or CYB5R3 and if expression is related to ovarian 
cancer prognosis, but there was no significant relationship 
for either gene (data not shown).
Figure 5: Functional validation of ABHD2 as a negative regulator of anoikis resistance in OVCA420 cells. a. Number 
of viable control, sh1-OVCA420 and sh2-OVCA420 cells following incubation on ultra-low attachment plates (n=6). b. Representative 
data showing Annexin V/7-ADD staining following incubation on ultralow attachment plates. c. Comparison of the ratio of the Annexin 
V(-)/7-ADD(-) fraction (viable cells) and Annexin V(+) fraction (apoptotic cells) between control, sh1 and sh2 cells. d. Number of viable 
OVCA420-control and OVCA420-ABHD2 cells following incubation on ultra-low attachment plates (n=6). Panels a-c: sh1; sh1-OVCA420, 
sh2; sh2-OVCA420, control; control-OVCA420; panel d: control; OVCA420-control, ABHD2; SKOV3-ABHD2.
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Alteration of platinum sensitivity by decreased 
ABHD2 expression in vitro
Because decreased expression of ABHD2 is related 
to platinum resistance in clinical samples, we investigated 
whether suppression of ABHD2 could confer resistance to 
platinum in vitro. We cultured sh1-ABHD2, sh2-ABHD2 
and control- OVCA420 cells with 10 μM CDDP for 24 
hours, followed by 7AAD staining to detect dead cells. The 
ratio of 7AAD-negative cells was significantly increased 
in sh1-ABHD2 and sh2-ABHD2 cells as compared to that 
of control cells (p<0.0001, Figure 9a, 9b). We determined 
the CDDP IC50 values at 72 hours and found that sh1-
ABHD2 and sh2-ABHD2 cells exhibited significantly 
higher IC50 values than that of control cells (p=0.013, 
p=0.014, respectively, Figure 9c, 9d). Additionally, we 
examined sensitivity to Carboplatin (CBDCA) through 
identification of dead cells and comparison of IC50 
values. The results were consistent with those of CDDP 
(p<0.0001, Figure 9e, 9f, p<0.0001, Figure 9g, 9h). 
Furthermore, we used another HGSOC cell line, CAOV3, 
and investigated whether suppression of ABHD2 could 
also confer resistance to platinum. We established sh1-
CAOV3 cells and control cells in the same manner, and 
found that sh1-CAOV3 cells were significantly more 
resistant to CDDP (Supplementary Figure S4a, S4b). 
Therefore, suppression of ABHD2 confers resistance to 
platinum in vitro.
Figure 6: Functional validation of ABHD2 as a negative regulator of anoikis resistance in SKOV3 cells. a. Number 
of viable SKOV3-control and SKOV3-ABHD2 cells following incubation on ultra-low attachment plates (n=6). b. Representative data 
showing Annexin V/7-ADD staining following incubation on ultralow attachment plates. c. Comparison of the ratio of the Annexin V(-)/7-
ADD(-) fraction and Annexin V(+) fraction between SKOV3-control and SKOV3-ABHD2 cells. d. Number of viable control- SKOV3, 
sh1- SKOV3-ABHD2 and sh2-SKOV3-ABHD2 cells following incubation on ultra-low attachment plates (n=6). e. Representative data 
showing Annexin V/7-ADD staining following incubation on ultralow attachment plates for 48 hours. f. Comparison of the ratio of the 
Annexin V(-)/7-ADD(-) fraction and Annexin V(+) fraction among control, sh1-SKOV3-ABHD2 and sh2-SKOV3-ABHD2 cells. Panels 
a-c: control; SKOV3-control, ABHD2; SKOV3-ABHD2; panels d-f: control; control-SKOV3-ABHD2, sh1; sh1-SKOV3-ABHD2, sh2; 
sh2-SKOV3-ABHD2.
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Side population and ABHD2 expression
The side population (SP) cell fraction refers to the 
small population of cells that have a high capacity to 
efflux Hoechst dye 333432. Because an increase in the 
SP fraction is reported to be associated with resistance to 
anoikis [24], we investigated if the SP fraction is altered 
by suppression of ABHD2 expression in OVCA420 cells. 
We found that the SP fraction of sh1-ABHD2 and sh2-
ABHD2 cells was significantly higher than that of control 
cells (p<0.001, p<0.0001, respectively, Supplementary 
Figure S5).
DISCUSSION
In this research, we performed a functional 
genomics screen using an shRNA library to search for 
drivers of anoikis resistance in HGSOC. This is the 
first report that refers to a positive screen about anoikis 
resistance, an unique function of HGSOC, using a 
shRNA library. Consequently, we successfully identified 
three genes, ABHD2, ELAC2 and CYB5R3 whose 
downregulation increased resistance to anoikis (Figure 1). 
mRNA expression from these three genes was lower in 
ovarian cancer tissue, especially in HGSOC relative to 
SBT or normal ovarian epithelium (Figure 2, 3, 4). Also, 
we found that loss of the chromosomal regions where 
these three genes are located occurred frequently in 
HGSOC (Figure 2, 3, 4). Thus, our functional genomics 
Figure 7: Regulation of ERK1/2 and p38MAPK pathways by ABHD2. All experiments were performed in triplicate. 
a. Phosphorylated p38 (P-P38) and phosphorylated ERK1/2 (P-ERK1/2) increased following knockdown of ABHD2 (sh1 and sh2) in 
OVCA420 cells. On the contrary, P-P38 and P-ERK1/2 decreased following overexpression of ABHD2 in SKOV3 and OVCA420 cells. 
b. Resistance of OVCA420 cells to anoikis on ultra-low attachment dishes was inhibited by GSK1120212, a specific inhibitor of the 
ERK1/2 pathway. Reduction of P-ERK1/2 following treatment with GSK1120212 was confirmed by Western blotting. DMSO, vehicle 
control. Cells were treated with differing doses of GSK1120212 as indicated. c. Resistance of OVCA420 cells to anoikis was inhibited 
following treatment with SB203580, a specific inhibitor of the the p38MAPK pathway. d. Levels of P-P38 and P-ERK1/2 increased 
following knockdown of ABHD2 (sh1 and sh2) in SKOV3-ABHD2 cells. e. Resistance to anoikis in sh1-SKOV3-ABHD2 and sh2-SKOV3-
ABHD2 cells was inhibited following treatment with 100nM GSK1120212 (GSK) and 30μM SB203580 (SB).”
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screen was useful in identifying driver changes involved 
in malignant phenotypes of HGSOC among the numerous 
copy number alterations that are characteristic of this 
disease. Similar to our results, the REST gene, identified 
as a tumor suppressor by using an shRNA library, is in a 
frequently deleted chromosomal location in colon cancer 
[13]. We found that DNA methylation and mutation were 
not related to downregulation of the three genes identified 
in HGSOC. These results are compatible with the prior 
findings that HGSOC is characterized by ubiquitous 
mutation of TP53 and extensive copy number alterations, 
rather than other driver mutations and DNA methylation 
[25].
The immortalized human ovarian epithelial cell 
line HOSE/E7, established by transfection of hTERT and 
E7, does not form colonies in soft agar [21]. We found 
that shRNA library-transduced HOSE/E7 cells were also 
unable to form colonies in soft agar (Figure 1a).
Moreover, among the HGSOC cell lines that do 
not form colonies in soft agar, only OVCA420 formed 
colonies after transfection of the shRNA library. The 
publicly available microarray data [8] indicated that 
OVCA420 had higher ABHD2 expression than the other 
cell lines (data not shown). This may be one reason that 
suppression of ABHD2 expression caused resistance to 
anoikis only in the OVCA420 cells. Expression of ELAC2 
and CYB5R3, however, did not differ between OVCA420 
and the other cell lines (data not shown). Therefore, the 
biological differences between OVCA420 and the other 
cell lines remain to be elucidated.
Among the three genes that we identified, we 
further analyzed ABHD2 because low expression is a 
poor prognostic factor for HGSOC and there was an 
available antibody. ABHD2 is a member of the alpha/
beta hydrolase family. It was originally identified as a 
gene whose expression is suppressed in pulmonary 
emphysema [26]. Defects in ABHD2 cause an increase of 
smooth muscle cell migration and of intimal hyperplasia. 
ABHD2 deficient mice develop spontaneous gradual 
progression of emphysema [27, 28]. There are no prior 
reports of a relationship between ABHD2 and cancer. The 
intimal cell hyperplasia caused by suppression of ABHD2 
might be related to apoptosis resistance observed in 
cancer cells. Suppression of another alpha/beta hydrolase 
member, ABHD4, was found to increase resistance to 
anoikis in RWPE-1 prostate cancer cells [29]. In our 
study, we found that suppression of ABHD2 increases 
anoikis resistance through the ERK1/2 and p38MAPK 
pathways in HGSOC (Figure 7). How ABHD2 affects 
changes in the ERK1/2 and p38MAPK pathways remains 
to be determined.
Intriguingly, we found a significant correlation 
between low expression of ABHD2 and platinum-
resistance in our clinical data analysis (Table 1). Further, 
suppression of ABHD2 caused platinum resistance in 
vitro (Figure 9, Supplementary Figure S4). A correlation 
Table 1: ABHD2 expression levels and clinicopathological factors
H-score <110 (n=15) >120 (n=21) p-value
Age 55.8 56.9 0.89
FIGO stage
1,2 4 5
3,4 11 16 0.69
Ascites
+ 12 12
- 3 9 0.28
Clinical platinum sensitivity
Sensitive 9 20
Resistance 6 1 0.013
LVSI
+ 11 9
- 4 12 0.096
Lymph node metastasis
+ 8 6
- 5 14 0.15
(unknown) 2 1
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between anoikis resistance and platinum resistance was 
previously reported in HGSOC [30]. Moreover, it was 
also reported that ERK1/2 and p38MAPK pathway 
activation causes platinum resistance [31, 32]. It is also 
known that resistance to anoikis is a characteristics of 
cancer stem cells (CSC), and CSC have high drug efflux 
potential, thus inherent platinum resistance [6]. In our 
study, suppression of ABHD2 increased the SP fraction of 
OVCA420 cells, a characteristic feature of CSC [33, 34, 
35] (Supplementary Figure S5). The increase in colony 
formation in soft agar may indeed reflect an increase in 
stemness characteristics, but to demonstrate this would 
require a great deal of further work that is beyond the 
scope of the present manuscript. It was shown previously 
that suppression of MKP3, DDB2 and DOK2 increased 
resistance to anoikis, chemoresistance and enhanced the 
CSC phenotype of HGSOC [36, 37, 38]. Therefore, our 
results are consistent with those findings. Although the 
detailed molecular mechanisms by which suppression 
of ABHD2 is involved in platinum-resistance remain 
unclear, our findings could be useful for development of a 
biomarker for individualized treatment of HGSOC.
In conclusion, we found that suppression of ABHD2, 
ELAC2 or CYB5R3 caused resistance to anoikis through a 
functional genomics screen. Loss of copy number of the 
loci containing these three genes was frequent in HGSOC, 
and as such may contribute to the HGSOC carcinogenic 
process. Suppression of ABHD2 increased not only anoikis 
resistance, but also platinum-resistance. Our studies 
provide support for future research exploring previously 
Figure 8: Overall survival of ovarian cancer patients. a. Differences in survival based on ABHD2 immunohistochemical scores 
(H-score) in HGSOC. b. Differences in survival based on ABHD2 mRNA expression in GSE9891 (n=285, mostly HGSOC) and GSE3149 
(n=146, mostly HGSOC) datasets. Samples were divided into high (greater than the median value) and low (less than the median) expression 
cases. c. Analysis of HGSOC patients (n=36) from KOV-75 based on ABHD2 mRNA expression. d. Analysis of non-HGSOC patients 
(n=39) from KOV-75 based on ABHD2 mRNA expression. n.s., not significant.
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undiscovered factors relevant to malignant phenotypes of 
HGSOC.
MATERIALS AND METHODS
Cell lines and reagents
We maintained human serous ovarian cancer cell 
lines including OVCA420, OVCA433, OVCA429, 
TYK-nu, SKOV8, CAOV3, DOV13, HEYA8, A2780 
and SKOV3 [8], in RPMI 1640 (Nacalai Tesque, Kyoto, 
Japan) supplemented with 10% fetal bovine serum (FBS) 
and 100 IU/ml penicillin and 100 μg/ml streptomycin 
(Nacali Tesque). The immortalized human ovarian 
surface epithelial cell line, HOSE-E7 [20], kindly 
provided by Dr. Katabuchi at Kumamoto University, 
was cultured in DMEM/F12 (Thermo Fisher Scientific, 
Waltham, USA) supplemented with 10% FBS and 100 
IU/ml penicillin and 100 μg/ml streptomycin (Nacalai 
Tesque). 293FT cells were purchased from Thermo 
Fisher Scientific, and cultured in DMEM (Thermo Fisher 
Scientific) supplemented with 10% FBS and 100 IU/ml 
penicillin and 100 μg/ml streptomycin. All cells were 
seeded into Cellstars® tissue culture plates (Greiner, 
Frickenhausen, Germany) in a humidified incubator 
containing 5% CO2 at 37°C. All cell lines were regularly 
tested for mycoplasma.
As an inhibitor of the p38 MAPK pathway, we used 
SB203580 (Sigma-Aldrich, St.Louis, USA). To inhibit the 
ERK1/2 pathway, we used GSK1120212 (Sigma-Aldrich).
Figure 9: Suppression of ABHD2 causes platinum resistance. a. Representative data showing 7-ADD staining following 24 hour 
incubation with 10 μM cisplatin. b. The ratio of the 7-AAD negative live OVCA420 cells markedly increased following suppression of 
ABHD2 (sh1 and sh2) as compared to the control after 24 hour incubation with 10 μM cisplatin (n=3). c. Dose-response curves following 
incubation of OVCA420 cells with the indicated concentrations of cisplatin for 72 hours (n=6). d. Cisplatin IC50 values increased following 
suppression of ABHD2 in OVCA420 cells. e. Representative data showing 7-ADD staining following 24 hour incubation with 100 μM 
Carboplatin. f. The ratio of 7-AAD negative live OVCA420 cells markedly increased following suppression of ABHD2 (sh1 and sh2) as 
compared to the control following a 24 hour incubation with 100 μM carboplatin (n=3). 
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Soft agar colony formation assay
Soft agar colony formation assays were performed 
as previously described [39]. Briefly, the lower layer 
consisted of 1x media (RPMI1640 or DMEM/F12 with 
10% FBS) and 0.6% low melting point agarose. Plates 
were chilled at room temperature until the agarose was 
solidified. The upper layer consisted of cells suspended in 
1x media and 0.3% low melting point agarose. We added 
1x medium to the top of the upper layer twice weekly. On 
day 21, we counted colonies that had attained a diameter 
of >100 μm.
First shRNA library screening
We transfected the DECIPHER RNAi library 
Module (Cellecta, Mountain View, USA), a pRSI12 
backbone lentiviral shRNA library comprising ~80 000 
plasmids targeting ~15 000 genes into cells according 
to the manufacturer’s instructions. In order to generate 
lentiviruses, we used Lipofectamin 2000 (Thermo Fisher 
Scientific) and Virapower (Thermo Fisher Scientific), and 
used 293FT cells as the packaging cells to generate the 
viral supernatant. Following 72 hours of selection with 
puromycin (Thermo Fisher Scientific), 3.6x106 stably 
transduced cells were suspended in 0.3% soft agar with 
1x media for soft agar colony assays as described above. 
In the first screening, we used twelve 10 cm dishes per 
cell line (3.0 x 105 cells per dish). On day 21, colonies 
>100 μm were picked using 200 μl pipette tips (Nippon 
Genetics, Tokyo, Japan) under a microscope. Each colony 
was seeded into one well of a 96-well plate with culture 
medium and expanded until about 80% confluent in one 
well of a 24-well dish. We then extracted DNA using the 
DNeasy Blood and Tissue Kit (Qiagen, Venlo, Nederland) 
for subcloning.
Subcloning and reconstruction of shRNA 
plasmids, followed by the second screening
In the pRSI12 lentiviral vector, an shRNA target 
sequence is located between ClaI and XbaI sites. We 
amplified shRNA target sequences of DNA extracted 
from the colonies grown in soft agar by PCR using the 
primers listed in Supplementary Table S3. Cycling 
parameters were 98°C for 5 minutes, followed by 30 
cycles of 98°C for 10 seconds, 63°C for 10 seconds and 
72°C for 30 seconds, followed by 72°C for 10 minutes. 
All the primers used in this study were purchased from 
Greiner. The amplified PCR products were subcloned 
into the original pRSI12 lentiviral vector at the ClaI and 
XbaI sites using the InFusion HD cloning Kit (Takara Bio, 
Otsu, Japan) according to the manufacturer’s protocol, 
thus reconstructing pRSI12 shRNA lentiviral plasmids 
that were identical to those included in the original shRNA 
library. To identify the cloned shRNAs, we read the sense 
and anti-sense sequences by Sanger sequencing (3130xl 
Genetic Analyzer) (Thermo Fisher Scientific) using 
primers listed in Supplementary Table S3. In the second 
screening with the soft agar colony formation assay, we 
seeded 2.0x104 cells per well in 6-well dishes.
RNA extraction and real time quantitative PCR
Total RNA was extracted using the RNeasy® 
Mini Kit (Qiagen). RNA reverse transcription was 
performed using the Transcriptor High Fidelity cDNA 
Synthesis Kit (Roche, Basel. Switzerland) according 
to the manufacturer’s instructions. Quantitative reverse 
transcriptase (RT)-PCR reactions of genes potentially 
targeted by shRNAs and Beta-Actin (ACTB) were 
performed using the Light Cycler 480-II (Roche) and 
a Mono Color Hydrolysis Universal Probe System 
(Roche). Primer sets were designed using the Universal 
Probe Library Assay Design Center (https://www.
roche-applied-science.com/sis/rtpcr) and purchased 
from Greiner. Primer sets are listed in Supplementary 
Table S1. Cycling parameters were 95°C for 10 minutes 
followed by 45 cycles of 95°C for 10 seconds, 60°C for 
30 seconds and 72°C for 1 second, followed by 40°C 
for 30 seconds. Relative mRNA expression levels were 
determined according to the ΔΔCt method, and values 
were normalized to ACTB expression.
Bisulfite sequencing of cloned alleles
Methylation was analyzed by bisulfite PCR 
sequencing of cloned alleles. We extracted DNA from two 
ovarian cancer cell lines, A2780 and HEYA8, and from 
HGSOC tissue of eight patients using the DNeasy Blood 
and Tissue Kit (Qiagen). Two μg DNA was modified with 
sodium bisulfite treatment using the Bisulfite Kit (Qiagen) 
according to the manufacturer’s protocol. We designed 
forward and reverse primers (Supplementary Table S1) 
that were used to amplify bisulfite modified DNA across 
the ABHD2 promoter region. PCR products were purified 
using the QIAquick PCR Purification Kit (Qiagen), cloned 
into the TOPO-TA vector (Thermo Fisher Scientific) and 
sequenced following the manufacturer’s standard protocol. 
Between 13 and 20 clones were sequenced for each 
sample.
Stable knockdown and overexpression of 
ABHD2
TRC lentiviral ABHD2-specific shRNAs (GE 
Healthcare Life Science, Backinghamshire, UK) were 
transfected into OVCA420 cells as recommended 
by the manufacturer. Stably transfected cells were 
selected with puromycin (Thermo Fisher Scientific). 
We used two kinds of shRNAs whose target sequences 
were different from that of the sequence within the 
library of shRNAs. Target sequences were as follows; 
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Sh1:ATGAGGAAGTTGTAGAACCGC, Sh2: 
TTACGCTCCCATTGGCAAATG. We also transfected 
non-silencing control TRC lentiviral shRNA plasmid into 
cells in the same manner.
We purchased precision LentiORF ABHD2 plasmids 
(GE Healthcare Life Science), and transfected SKOV3 
cells as recommended by the manufacturer. Stably 
transfected cells were selected with blasticidin (10ug/ml, 
Thermo Fisher Scientific). We also transfected control 
Precision LentiORF in the same manner.
Western blot
Western blot was performed as previously reported 
[40]. Primary antibodies were anti-ABHD2 rabbit 
polyclonal antibody (1:250, Abgent AP13083c, San Diego, 
USA), anti-phospho ERK1/2 rabbit monoclonal antibody 
(1:1,000, Cell Signal Technology, 197G2, Danver, 
JAPAN), anti-ERK1/2 rabbit monoclonal antibody 
(1:1000, Cell Signal Technology, 137F5), anti-phospho 
p38 MAPK rabbit monoclonal antibody (1:1000, Cell 
Signal Technology, (D13E1)XP) anti-p38MAPK rabbit 
monoclonal antibody (1:1000, Cell Signal Technology, 
(D3F9)XP) and anti-GAPDH mouse monoclonal antibody 
(1:1000, Abcam, ab8245, Cambridge, UK). After washing 
in tris-buffered saline (TBS)-T, the blots were incubated 
with the appropriate peroxidase-coupled secondary 
antibody (1:2000; Anti-rabbit HRP or anti-mouse HRP, GE 
Healthcare Life Science). Specific proteins were detected 
using ECL Plus Western Blotting Reagent (GE Healthcare 
Life Science). The bands were visualized using Molecular 
Imager Gel DocTMXR+ and ChemiDocTMXRS+ 
Systems with Image Lab 2.0 software (Bio-Rad).
Anoikis assays
Cells (1.0x105 per well) were plated onto ultralow 
attachment 6-well plates (Corning, NY, USA) in 1x 
media to prohibit attachment. After incubation for 7 
days, we collected cells and incubated them in trypsin-
EDTA (0.25%) (Thermo Fisher Scientific) and Accumax 
(Innovative cell Technologies, San Diego, USA) for 
cell dissociation. We counted the total number of viable 
cells using a hemocytometer. Experiments were repeated 
in triplicate. Dead cells were excluded by trypan blue 
staining.
Apoptosis assays
Cells were cultured in ultralow attachment plates 
(Corning) for 24 (OVCA420) or 48 (SKOV3) hours. The 
fraction of apoptotic cells was analyzed by MACSquant 
(MACSQuant) (Milteney Biotec, Cologne, Germany) 
following staining with APC-labeled annexin V and 
7-Amino-actinomycin D (7AAD) (Becton, Dickinson and 
Company; BD, Franklin Lakes, USA) according to the 
manufacturer’s protocol. Experiments were repeated at 
least three times.
Cell proliferation assay
Cells were seeded into 96-well tissue culture 
plates at 2x103 cells per well. At 8, 24, 48 and 72 
hours cell viability was determined using the WST-1 
assay kit (Premix WST-1®, Takara Bio) following the 
manufacturer’s instructions. The absorbance values at 
450nm were normalized by values at 8 hours following 
subtraction of values obtained from vacant wells.
Platinum sensitivity assay
Cells were plated into 96-well plates at 2000 cells 
(OVCA420) or 3000 cells (CAOV3) per well. 24 hours 
later, the culture medium was replaced by fresh medium 
containing various concentrations of cisplatin (Nippon 
Kayaku, Kyoto, Japan) or carboplatin (Bristol Myers 
Squibb, NY, USA) for 72 hours. The percentage of viable 
cells was then examined using the WST-1 assay kit 
following the manufacturer’s instructions. All cytotoxicity 
data shown are the means of at least three independent 
experiments.
7AAD (BD) staining was also performed to evaluate 
cytotoxicity. Following incubation with 10 μM CDDP 
or 100 μM CBDCA for 24 hours, cells were collected 
and stained with 2 μg/mL 7AAD. Dead cells were 
detected by flow cytometry (MACSQuant) following the 
manufacturer’s instructions (BD).
Patients and tissues
Ovarian tumor specimens and clinicopathological 
information were obtained from 36 patients with HGSOC, 
8 patients with serous borderline tumor (SBT) and normal 
fallopian tube from 11 women, all of whom underwent 
primary surgery at Kyoto University Hospital between 
1998 and 2014. All samples were obtained at the time 
of initial surgery without prior chemotherapy. Patient 
characteristics are listed in Supplementary Table S4. All 
tissue specimens were collected after obtaining written 
consent from patients with the approval of the Facility 
Ethical Committee, with approval number G288 (Nov 29th, 
2013). All samples were fixed in 10% buffered formalin, 
embedded in paraffin, and sectioned.
Immunohistochemical staining
Immunohistochemical staining was done using 
the streptavidin-biotin peroxidase complex method as 
previously reported [40]. Slides were incubated with a 
rabbit anti-ABHD2 antibody (Abgent) at a 1:40 dilution 
overnight at 4°C, followed by a one-hour incubation 
with biotinylated goat anti-rabbit secondary antibodies 
(Nichirei, Tokyo, Japan) at room temperature. Two 
Oncotarget15www.impactjournals.com/oncotarget
examiners (KY and NM) independently evaluated the 
staining in a blinded fashion. We used the H-score to take 
staining intensity and proportion into consideration [41]. 
The score was assigned by a formula, i.e. 2 x percentage 
of a strongly stained area, 1 x percentage of a weakly 
stained area, imparting a total score ranging from 0 to 
200. Staining intensity was assigned as weak, moderate 
or strong.
Gene expression microarray datasets and copy 
number dataset
Microarray datasets were obtained from the Gene 
Expression Omnibus website (http://www.ncbi.nlm.
nih.gov/gro). We used five gene expression microarray 
datasets (GSE2109, GSE6008, GSE3149, GSE9891, 
GSE55512 and GSE39204) to analyze differences in gene 
expression between ovarian cancer, ovarian borderline 
tumors and normal ovarian surface epithelium. Data from 
GSE55512 and GSE39204, both from our institution, were 
combined and termed KOV-75 [42, 43]. The cBioPortal 
database (http://www.cbioportal.org/public-portal/) was 
used to analyze copy number alterations and methylation 
status in HGSOC samples in The Cancer Genome Atlas 
(TCGA, 2011).
Side population (SP) analysis
Cells were detached by trypsinization, centrifuged 
and resuspended in tissue culture medium containing 10% 
serum at a concentration of 1x106 cells/mL.
At the end of the incubation, the cells were 
centrifuged and resuspended in cold PBS with 2% serum. 
The side population (SP) of cells was analyzed using a 
BD FACS AriaII system (BD) as previously reported [24]. 
The cells were labeled with 5.0 μg/mL of Hoechst33342 
dye (Sigma-Aldrich) at 37°C for 90 min either alone or in 
combination with 15 μM Reserpine (Sigma-Aldrich), an 
ABC efflux pump inhibitor. 7AAD was added to the cells 
at a final concentration of 2 μg/mL prior to flow cytometry 
analysis to exclude the dead cells. The Hoechst dye was 
excited with UV laser and fluorescence was measured with 
both 675LP (Hoechst Red) and 440/40 filters (Hoechst 
Blue).
Statistical analysis
Group comparisons were performed using unpaired 
t-tests. Prognostic analyses were performed using the log-
rank test and multivariate analyses. Clinicopathological 
analyses were performed using Fisher’s exact tests. All 
statistical analyses were done using GraphPad Prism 
6.0 and R software. Probability values below 0.05 were 
considered significant.
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